Ideaya Biosciences (IDYA) announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial OptimUM-02 evaluating darovasertib, the company’s investigational oral protein kinase C inhibitor, in combination with Pfizer’s (PFE) crizotinib, an oral c-MET inhibitor, in first line HLA A2-negative metastatic uveal melanoma. Ideaya expects to report median progression-free survival data from this trial in the first quarter 2026 to support a potential accelerated approval filing in the United States.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Promising Future with Innovative Dual KAT6/7 Inhibitor and Strong Financial Position
- Ideaya Biosciences submits IDE574 IND application to FDA
- Ideaya financials not impacted by GSK termination, says Mizuho
- Ideaya disclosed termination of GSK license agreement
- IDEAYA Biosciences: Strategic Positioning and Promising Oncology Assets Drive Buy Rating